舒晓宏 职务: 教授 专业: 药理学 教育/工作经历Education/Working Experience

EDUCATION

1993-1997 BA Shenyang Pharmaceutical University Traditional Chinese Medicine

2000-2003 Master Dalian Medical University Biochemistry and molecular biology

2006-2010 Ph.D Dalian Medical University Biochemistry and molecular biology

2010-2012 post-doc Dalian Hanxin Biopharmaceutical Co Ltd Biology

Working Experience

1997-2002 Assistant Dalian Medical University Schoolof Pharmacy

2002-2007 Lecturer Dalian Medical University Schoolof Pharmacy

2007-2012 Associate Professor Dalian Medical University Schoolof Pharmacy

2012- Professor Dalian Medical University Schoolof Pharmacy

2014- Visiting Scholar University of Virginia School ofMedicine 学术团体Participation in the Academic Community

Chinese Pharmacological Society

Cell and molecular biology society of Liaoning Province 科研项目/基金Research Projects/Grants

1. The Outstanding Young Scholars Growth Plans of Colleges and Universities in Liaoning Province, China (Grant No. LJQ2012078). PI. Xiaohong Shu Ph. D. Total cost:￥60,0002012/01-2014/12

2.The National Natural Science Foundation of China (Grant No. 81072063). PI. Xiaohong Shu Ph. D. Total cost:￥330,0002011/01-2013/12

3. China Postdoctoral Science Foundation (Grant NO.20100481217). PI. Xiaohong Shu Ph. D. Total cost:￥30,0002010/09-2012/12. 录取计划/招收标准

Admission Plan/

Requirements

Admission plan:1 person (English)

1. Zan GY, Wang Q, Wang YJ, Chen JC, Wu X, Yang CH, Li M, Liu Y, Hu XW, Shu XH*, Liu JG*. p38 mitogen-activated protein kinase activation in amygdala mediatesκopioidreceptor agonist U50,488H-induced conditioned place aversion. Neuroscience. 2016;320:122-8.

2.Shu XH, Wang LL, Li H, Song X, Shi S, Gu JY, Wu ML, Chen XY, Kong QY, LiuJ.Diffusion Efficiency and Bioavailability of Resveratrol Administered to Rat Brain by Different Routes: Therapeutic Implications. Neurotherapeutics. 2015;12(2):491-501.

3.Shu XH, Keller TC 4th, Begandt D, Butcher JT, Biwer L, Keller AS, Columbus L,Isakson BE. Endothelial nitric oxide synthase in the microcirculation. Cell Mol Life Sci. 2015;72(23):4561-75.

4. Hu Y, Li S, Liu F, Geng L,Shu XH*, Zhang J*. Discovery of novel nonpeptideallosteric inhibitors interrupting the interaction of CDK2/cyclin A3 by virtual screening and bioassays. Bioorg Med Chem Lett. 2015;25(19):4069-73.

5.Shu XH, Sun XX, Li H, Song X, Wang LL, Shi S, Liu J. Resveratrol inducesapoptosis of medulloblastoma cells without affecting astrocytes and neurons. Pediatr Blood Cancer. 2014;61(s2):339-40.

6. Hu Y, Li C, Li H, Li M,Shu XH*. Resveratrol-mediated reversal of tumormulti-drug resistance. Curr Drug Metab. 2014;15(7):703-10.

7. Shu XH, Li H, Sun XX, Sun Z, Wu ML, Kong QY, Liu J. Bioactive form ofresveratrol in glioblastoma cells and its safety for normal brain cells. Functional Foods in Health and Disease. 2013;3:146-53.

8.杨阳,李传刚,舒晓宏*.白藜芦醇代谢模式的研究进展.中国药学杂志.2013;48:2081-3

9.Shu XH, Li H, Sun XX, Wang Q, Wu ML, Kong QY, Liu J. Metabolic patterns andbiotransformation activities of resveratrol in human glioblastoma cells: relevance with therapeutic efficacies. PLoS One. 2011;6:e27484.

10.Shu XH,Li H, Sun Z, Wu ML, Ma JX, Wang JM, Wang Q, Sun Y, Fu YS, Chen XY,Kong QY, Liu J. Identification of metabolic pattern and bioactive form of resveratrol in human medulloblastoma cells. Biochem Pharmacol. 2010;79(10):1516-25